MET and glioblastoma: A pre-clinical study has shown potent synergistic effects in mice bearing patient-derived glioblastoma tumours treated with a combination of crizotinib plus erlotinib.242 Therefore, this combination may be a worthy therapeutic strategy to explore in the clinic to delay treatment resistance and increase survival in EGFRvIII+/c-Met+ glioblastoma patients.